 |
|
|
|
October 1999 Cover
|
|
Pasteur Merieux Connaught announced that its new HIV vaccine induced immune responses in patients during phase II trials. Representatives from the company
said that 90 percent of patients receiving the combination vaccine developed antibodies to HIV, and 33 percent developed anti-HIV immune cells. Company officials
said this was the largest phase II trial of an AIDS vaccine ever.
Editor's Note: from the Wall Street Journal
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
